# Massive Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/massive-bio

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.massivebio.com
- Total disclosed funding: $3.6M
- Latest round: Seed (Apr 10, 2019)
- Investors on record: 2

## About

Massive Bio is a technology-driven company specializing in connecting cancer patients to clinical trials through an AI-powered platform, enhancing accessibility and improving patient outcomes in oncology.Founded in 2014 in New York, US, Massive Bio focuses on revolutionizing the clinical trial process for cancer patients. The company has completed 5 deals, with its most recent funding round occurring on June 2, 2022. The latest round raised USD 9.00 mn, co-led by Revo Capital and DEG. The company's founders include Arturo Loaiza-Bonilla, Selin Kurnaz, and Çagatay Çulcuoglu, with Selin Kurnaz currently serving as CEO.Massive Bio offers an AI-powered platform that connects cancer patients with clinical trials, streamlining the matching process regardless of geographical location or financial constraints. Patients can share their medical history and receive instant feedback on eligibility for over 19,000 clinical trials worldwide. The platform integrates physician expertise with advanced algorithms, ensuring a tailored approach. Users include cancer patients, healthcare providers, pharmaceutical companies, and research organizations, all aimed at enhancing access to innovative cancer treatments.Massive Bio generates revenue through partnerships and subscription models targeting healthcare providers and patients. Their platform facilitates healthcare professionals in identifying suitable clinical trials, subsequently increasing referral rates and improving patient management. Revenue streams also arise from direct engagement with pharmaceutical companies and contract research organizations (CROs) seeking patient recruitment for ongoing trials. Although specific pricing plans are not disclosed, services include tailored reports and ongoing support throughout the clinical trial journey, providing value for both patients and institutional healthcare clients.In June 2022, Massive Bio raised USD 9.00 mn in venture funding to enhance its revenue-generating operations and expand AI-based technology solutions for oncology clinical trials. The funding will support the development of new products aimed at improving patient engagement and streamlining operations. The company is also targeting expansion into new geographic markets, particularly in Europe and Asia, by 2024, aiming to increase accessibility to its services and further support cancer patients worldwide.

## Funding rounds

- Seed, Apr 10, 2019, $2.5M — UL Ventures, International Private Bank
- Seed, Jul 16, 2018, $1.1M — UL Ventures

## Investors

- UL Ventures (https://capitalatlas.ai/funds/ul-ventures) — Seed
- International Private Bank — Seed